Thaís Larré Oliveira Bohn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thaís Larré Oliveira Bohn has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Odir Antônio Dellagostin
Laboratório de Vacinologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brasil
3 shared publicationsAna C. K. Pedra
Laboratório de Vacinologia, Núcleo de Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brazil
2 shared publicationsNatasha R. de Oliveira
Laboratório de Vacinologia, Núcleo de Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brazil
2 shared publicationsNatasha Rodrigues de Oliveira
Laboratório de Vacinologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brasil
2 shared publicationsOdir A. Dellagostin
Laboratório de Vacinologia, Núcleo de Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas, Brazil
2 shared publications- Odir Antônio Dellagostin
Núcleo de Biotecnologia, Centro de Desenvolvimento Tecnológico, Universidade Federal de Pelotas, Pelotas 96010-610, Rio Grande do Sul, Brazil
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 679
A versatile plasmid platform for auxotrophic complementation in attenuated Mycobacterium bovis BCG
Background: Mycobacterium bovis BCG is widely used as a vaccine vector due to its safety, genetic stability, and immunomodulatory properties. However, current expression systems for BCG transformation rely on antibiotic resistance genes, raising biosafety concerns. Therefore, alternative strategies—such as the use of auxotrophic strains—are highly desirable. Our group previously employed BioBrick™ technology to construct the pUP500 plasmid series containing various mycobacterial promoters. We engineered these plasmids for the auxotrophic complementation of BCG ΔLeuD, a leucine-auxotrophic strain, using an antibiotic-free and BioBrick™-compatible approach. Methods and Results: The auxotrophic complementation cassette pAN- leuD was cloned into pUP500 plasmids. Subsequently, the egfp gene was inserted downstream of the promoters, the kanamycin resistance gene was removed, and fluorescence was assessed by flow cytometry, qPCR and confocal microscopy in BCG grown in 7H9 medium and inside macrophages. Auxotrophic complementation was confirmed by growth of transformants in non-selective medium and analysis of leuD expression, and plasmid stability was evaluated along six BCG generations. Strains harboring plasmids containing the pAN and HspX promoters exhibited stronger fluorescence levels both in vitro and within macrophages. In contrast, the 18 kDa promoter demonstrated marked activation specifically in the intracellular environment, driving robust gene expression inside macrophages. These expression patterns were significantly higher compared to strains carrying the Ag85B or Hsp60 promoters, as well as to the negative control. Except for the Hsp60 construct, all plasmids exhibited robust in vitro stability across six consecutive passages, supporting their potential as reliable expression systems for heterologous antigens in therapeutic and vaccine applications. Conclusions: We developed five BioBrick™-compatible plasmids with distinct promoters for auxotrophic complementation and antigen expression in BCG ΔLeuD, eliminating the need for antibiotic-based selection. This standardized plasmid series reduces vector-related variability in comparative studies and provides a diverse promoter repertoire that may enhance the stability and efficacy of recombinant BCG ΔLeuD strains, representing a valuable advancement for prophylactic and therapeutic vaccine development.
- 28 April 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 679
Open AccessA versatile plasmid platform for auxotrophic complementation in attenuated Mycobacterium bovis BCG
Background: Mycobacterium bovis BCG is widely used as a vaccine vector due to its safety, genetic stability, and immunomodulatory properties. However, current expression systems for BCG transformation rely on antibiotic resistance genes, raising biosafety concerns. Therefore, alternative strategies—such as the use of auxotrophic strains—are highly desirable. Our group previously employed BioBrick™ technology to construct the pUP500 plasmid series containing various mycobacterial promoters. We engineered these plasmids for the auxotrophic complementation of BCG ΔLeuD, a leucine-auxotrophic strain, using an antibiotic-free and BioBrick™-compatible approach. Methods and Results: The auxotrophic complementation cassette pAN- leuD was cloned into pUP500 plasmids. Subsequently, the egfp gene was inserted downstream of the promoters, the kanamycin resistance gene was removed, and fluorescence was assessed by flow cytometry, qPCR and confocal microscopy in BCG grown in 7H9 medium and inside macrophages. Auxotrophic complementation was confirmed by growth of transformants in non-selective medium and analysis of leuD expression, and plasmid stability was evaluated along six BCG generations. Strains harboring plasmids containing the pAN and HspX promoters exhibited stronger fluorescence levels both in vitro and within macrophages. In contrast, the 18 kDa promoter demonstrated marked activation specifically in the intracellular environment, driving robust gene expression inside macrophages. These expression patterns were significantly higher compared to strains carrying the Ag85B or Hsp60 promoters, as well as to the negative control. Except for the Hsp60 construct, all plasmids exhibited robust in vitro stability across six consecutive passages, supporting their potential as reliable expression systems for heterologous antigens in therapeutic and vaccine applications. Conclusions: We developed five BioBrick™-compatible plasmids with distinct promoters for auxotrophic complementation and antigen expression in BCG ΔLeuD, eliminating the need for antibiotic-based selection. This standardized plasmid series reduces vector-related variability in comparative studies and provides a diverse promoter repertoire that may enhance the stability and efficacy of recombinant BCG ΔLeuD strains, representing a valuable advancement for prophylactic and therapeutic vaccine development.
- Open Access
Recombinant Live-Attenuated Salmonella Vaccine for Veterinary Use
Vaccination is essential for maintaining animal health, with priority placed on safety and cost effectiveness in veterinary use. The development of recombinant live-attenuated Salmonella vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens. This review summarizes the progress made in this field, with a focus on clinical trials demonstrating the efficacy and commercial potential of RASVs in veterinary medicine.
Open AccessRecombinant Live-Attenuated Salmonella Vaccine for Veterinary Use
Vaccination is essential for maintaining animal health, with priority placed on safety and cost effectiveness in veterinary use. The development of recombinant live-attenuated Salmonella vaccines (RASVs) has enabled the construction of balanced lethal systems, ensuring the stability of plasmid vectors encoding protective antigens post-immunization. These vaccines are particularly suitable for production animals, providing long-term immunity against a range of bacterial, viral, and parasitic pathogens. This review summarizes the progress made in this field, with a focus on clinical trials demonstrating the efficacy and commercial potential of RASVs in veterinary medicine.
- 26 September 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-15
A systematic review on the selection of reference genes for gene expression studies in rodents: are the classics the best choice?
Rodents are commonly used as animal models in studies investigating various experimental conditions, often requiring gene expression analysis. Quantitative real-time reverse transcription PCR (RT-qPCR) is the most widely used tool to quantify target gene expression levels under different experimental conditions in various biological samples. Relative normalization with reference genes is a crucial step in RT-qPCR to obtain reliable quantification results. In this work, the main reference genes used in gene expression studies among the three rodents commonly employed in scientific research—hamster, rat, and mouse—are analyzed and described. An individual literature search for each rodent was conducted using specific search terms in three databases: PubMed, Scopus, and Web of Science. A total of 157 articles were selected (rats = 73, mice = 79, and hamsters = 5), identifying various reference genes. The most commonly used reference genes were analyzed according to each rodent, sample type, and experimental condition evaluated, revealing a great variability in the stability of each gene across different samples and conditions. Classic genes, which are expected to be stably expressed in both samples and conditions analyzed, demonstrated greater variability, corroborating existing concerns about the use of these genes. Therefore, this review provides important insights for researchers seeking to identify suitable reference genes for their validation studies in rodents.
- 26 September 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-15
A systematic review on the selection of reference genes for gene expression studies in rodents: are the classics the best choice?
Rodents are commonly used as animal models in studies investigating various experimental conditions, often requiring gene expression analysis. Quantitative real-time reverse transcription PCR (RT-qPCR) is the most widely used tool to quantify target gene expression levels under different experimental conditions in various biological samples. Relative normalization with reference genes is a crucial step in RT-qPCR to obtain reliable quantification results. In this work, the main reference genes used in gene expression studies among the three rodents commonly employed in scientific research—hamster, rat, and mouse—are analyzed and described. An individual literature search for each rodent was conducted using specific search terms in three databases: PubMed, Scopus, and Web of Science. A total of 157 articles were selected (rats = 73, mice = 79, and hamsters = 5), identifying various reference genes. The most commonly used reference genes were analyzed according to each rodent, sample type, and experimental condition evaluated, revealing a great variability in the stability of each gene across different samples and conditions. Classic genes, which are expected to be stably expressed in both samples and conditions analyzed, demonstrated greater variability, corroborating existing concerns about the use of these genes. Therefore, this review provides important insights for researchers seeking to identify suitable reference genes for their validation studies in rodents.
- 25 September 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-6
Production of recombinant cytokines and polyclonal antibodies for analysis of cellular immune response in golden Syrian hamster
Background The development of therapies and vaccines for various diseases often necessitates the analysis of cellular immunity. However, unlike other rodents, the limited availability of reagents for Syrian hamsters restricts immunological analysis, particularly in the determination of serum effector molecules such as cytokines. In this study, we aim to produce and characterize the cytokines IFN-γ, TGF-β, IL-6, IL-10, and TNF-α from Syrian hamsters in recombinant form and to generate polyclonal antibodies against them in rats. Methods and results Cytokine transcript sequences were cloned into expression vectors in E. coli. Recombinant proteins were produced, purified through affinity chromatography, and characterized by Western blot using an anti-6xHis monoclonal antibody. Rats were immunized with the recombinant proteins to generate polyclonal antibodies (pAbs). These pAbs were characterized by Western blot and titrated by indirect ELISA. The recombinant cytokines rTNF-α, rIL-10, rIFN-γ, rTGF-β, and rIL-6 were produced and specifically recognized at their expected molecular weights of 22.3 kDa, 19.8 kDa, 18.9 kDa, 11.8 kDa, and 22.9 kDa. pAbs were produced and demonstrated the ability to specifically recognize their target proteins with titers of 409,600 (rIL-10), 204,800 (rTNF-α), 102,400 (rIL-10), 51,200 (rTGF-β), and 25,600 (rIFN-ɣ). Conclusions The reagents produced represent a starting point for developing immunoassays to detect hamster cytokines, facilitating the analysis of cellular immunity in this biomodel.
- 25 September 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-6
Production of recombinant cytokines and polyclonal antibodies for analysis of cellular immune response in golden Syrian hamster
Background The development of therapies and vaccines for various diseases often necessitates the analysis of cellular immunity. However, unlike other rodents, the limited availability of reagents for Syrian hamsters restricts immunological analysis, particularly in the determination of serum effector molecules such as cytokines. In this study, we aim to produce and characterize the cytokines IFN-γ, TGF-β, IL-6, IL-10, and TNF-α from Syrian hamsters in recombinant form and to generate polyclonal antibodies against them in rats. Methods and results Cytokine transcript sequences were cloned into expression vectors in E. coli. Recombinant proteins were produced, purified through affinity chromatography, and characterized by Western blot using an anti-6xHis monoclonal antibody. Rats were immunized with the recombinant proteins to generate polyclonal antibodies (pAbs). These pAbs were characterized by Western blot and titrated by indirect ELISA. The recombinant cytokines rTNF-α, rIL-10, rIFN-γ, rTGF-β, and rIL-6 were produced and specifically recognized at their expected molecular weights of 22.3 kDa, 19.8 kDa, 18.9 kDa, 11.8 kDa, and 22.9 kDa. pAbs were produced and demonstrated the ability to specifically recognize their target proteins with titers of 409,600 (rIL-10), 204,800 (rTNF-α), 102,400 (rIL-10), 51,200 (rTGF-β), and 25,600 (rIFN-ɣ). Conclusions The reagents produced represent a starting point for developing immunoassays to detect hamster cytokines, facilitating the analysis of cellular immunity in this biomodel.
- 4 October 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 184, 106378
Characterization of cellular immune response in hamsters immunized with recombinant vaccines against leptospirosis based on LipL32:LemA:LigAni chimeric protein
- 4 October 2023
- Published by Elsevier in Microbial Pathogenesis
- Vol. 184, 106378
Characterization of cellular immune response in hamsters immunized with recombinant vaccines against leptospirosis based on LipL32:LemA:LigAni chimeric protein
- Open Access
Auxotrophic Mycobacterium bovis BCG: Updates and Perspectives
Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other pathogens. However, BCG vaccination has limited efficacy in protecting against adult forms of tuberculosis (TB), raises concerns about its safety in immunocompromised populations, compromises the diagnosis of TB through the tuberculin test and lacks predictability for successful antigen expression and immune responses to heterologous antigens. Together, these factors propelled the construction and evaluation of auxotrophic BCG strains. Auxotrophs of BCG have been developed from mutations in the genes required for their growth using different approaches and have shown the potential to provide a model to study M. tuberculosis, a more stable, safe, and effective alternative to BCG and a vector for the development of recombinant live vaccines, especially against HIV infection. In this review, we provide an overview of the strategies for developing and using the auxotrophic BCG strains in different scenarios.
Open AccessAuxotrophic Mycobacterium bovis BCG: Updates and Perspectives
Mycobacterium bovis BCG has been used for a century as the only licensed vaccine against tuberculosis. Owing to its strong adjuvant properties, BCG has also been employed as an oncological immunotherapeutic as well as a live vaccine vector against other pathogens. However, BCG vaccination has limited efficacy in protecting against adult forms of tuberculosis (TB), raises concerns about its safety in immunocompromised populations, compromises the diagnosis of TB through the tuberculin test and lacks predictability for successful antigen expression and immune responses to heterologous antigens. Together, these factors propelled the construction and evaluation of auxotrophic BCG strains. Auxotrophs of BCG have been developed from mutations in the genes required for their growth using different approaches and have shown the potential to provide a model to study M. tuberculosis, a more stable, safe, and effective alternative to BCG and a vector for the development of recombinant live vaccines, especially against HIV infection. In this review, we provide an overview of the strategies for developing and using the auxotrophic BCG strains in different scenarios.
- 1 December 2019
- Published by Elsevier in Tuberculosis
- Vol. 119, 101851
A standardized BioBrick toolbox for the assembly of sequences in mycobacteria
- 1 December 2019
- Published by Elsevier in Tuberculosis
- Vol. 119, 101851
A standardized BioBrick toolbox for the assembly of sequences in mycobacteria